6,678 trials
Hepatitis B · Hepatitis · Hepatitis, Viral, Human
Primary: Number of Participants With Protective Levels of Antibodies After Treatment — 63; 4 Participants
Blood Pressure · Electroconvulsive Therapy
Primary: Systolic Blood Pressure Change — 22.011; 38.908 mmHg
Schizophrenia
Primary: Steady-state Average Plasma Concentration (Cavg,ss) of Risperidone and Total Active Moiety — 5.150; 10.200; 43.730; 44.049 ng/mL
HIV Seropositivity · Metabolic Syndrome · Fatty Liver
Primary: Change in Liver Fat — 0.3; 0.6 % hepatic fat fraction
Hemophilia A With Inhibitors
Primary: Time to Tolerization With rFVIIIFc — 11.7 weeks
Cardiovascular Disease · Hypertension · Hyperlipidemia
Primary: Changing LDL Cholesterol — 100; 70 Mg/dl
Asthma
Primary: Change in Percent of Predicted Peak Expiratory Flow Rate (PEFR) at t15 — 59.56; 52.45 percentage of predicted
Panic Disorder
Primary: Change in Orexin Levels (Blood) +1 Minute
Chronic Pain · Ankle Fracture Surgery · Regional Anesthesia
Primary: Pain Score at 12 Months - Experimental Group vs. Control Group — 36.33; 44.00 units on a scale — p=0.1269
Chronic Myelogenous Leukemia
Primary: Percentage of Participants With Improvement in Imatinib Related Chronic Low Grade Non Hematologic Adverse Event (AE) After Switch to Treatment With Nilotinib at End of…
Cognitive Measures · Driving Simulator Performance
Primary: Number of Subjects Who Had a Driving Simulator Crash Event — 2; 0 Participants — p=0.50
Ulcerative Colitis
Primary: Serum Golimumab Concentration (μg/ml) — 3.3; 2.4 ug/ml
Type 2 Diabetes
Primary: Area Over Basal for Postprandial Glucose From 0 to 600min — 591; 220; 197 mg*/min/dL
Heart Failure · Type 2 Diabetes Mellitus
Primary: The Effect of Empagliflozin Versus Placebo on the Change in Urine Output. — 545; -113 mL — p== 0.005
Pouchitis
Primary: Percentage of Participants With Chronic or Recurrent Pouchitis Achieving Clinically Relevant Remission at Week 14 — 9.8; 31.4 percentage of participants — p=0.013